本文转自【央视新闻客户端】； 朝"问"健康，健康生活。现在体检越来越普及，不少人拿到报告看到"结节""息肉"等字眼都会心头一 紧。别太着急！说不定，你看到体检报告中的一些"异常"，只是虚惊一场。 体检报告上这些"异常" 或许是"虚惊一场" 首都医科大学附属复兴医院主任医师 林华：像纤维瘤或者一些增生性的瘤样变，这种结节定期观察就 可以。特别是这种多发的结节，两侧乳腺都有，一侧七八个纤维瘤甚至更多，而且大小不等，这种情况 就观察，有的可以通过药物调理，让结节保持稳定状态就可以。 息肉会变成癌吗？ 需要立即切掉吗？ 解决了"结节"的困惑，再来聊聊体检报告里的另一个"高频词"—— 息肉，不少人会问：像胆囊息肉、 胃肠息肉等这些息肉会变成癌吗？需要立即切掉吗？ 像常见的甲状腺结节、肺结节、胃肠息肉等这些身体里的"不速之客"，到底是不是癌症的前兆呢？需要 立即手术切除吗？ 体检时，不少人体内被查出有微小的甲状腺结节，这些结节可能会发展成甲状腺癌，最常见的是甲状腺 乳头状癌。超声检查可以帮助医生看清甲状腺结节的形态、有无钙化，快速确定是良性或者恶性。专家 建议，如果甲状腺肿瘤是良性的，5厘米以上考虑手术；如果是恶性的，一 ...

在临床中，放疗的应用场景非常广泛：对于早期肺癌、食管癌、宫颈癌等癌症，放疗可以达到与手术相 当的根治效果，尤其适合身体状况不适合手术的患者；对于中晚期癌症，放疗可以与手术、化疗等结合 使用，缩小肿瘤体积、缓解疼痛、控制病情进展，提升患者的生活质量，延长生存期；此外，对于一些 晚期转移性肿瘤，放疗还能起到姑息治疗的作用，减轻患者的症状，让患者在治疗期间更有尊严。 预防先行：主动预防+定期筛查，筑牢防癌第一道防线 从临床来看，很多癌症的发生都与不良生活习惯密切相关。比如长期吸烟、过量饮酒是肺癌、食管癌、 肝癌等多种癌症的重要诱因；高热量、高脂肪、低纤维的饮食结构，会增加结直肠癌、乳腺癌的发病风 险；缺乏运动、长期熬夜、精神压力过大，则会导致免疫力下降，为癌细胞的滋生提供"可乘之机"。 因此，养成戒烟限酒、均衡饮食、规律作息、适度运动的健康习惯，是预防癌症的基础。同时，定期进 行针对性的癌症筛查也至关重要，比如40岁以上人群定期做肺癌低剂量CT筛查，女性定期做乳腺癌、 宫颈癌筛查，结直肠癌高危人群定期做肠镜筛查等，能帮助我们更早发现潜在的病变，为治疗争取时 间。 精准放疗： 告别认知误区 它是抗癌重要利器 当不幸确 ...

Group 1 - The core message emphasizes that proper nutrition is a crucial aspect of cancer prevention and treatment, highlighting the importance of a balanced diet rich in vegetables, fruits, whole grains, and proteins [1][5][6] - Vegetables are identified as the "main force" against cancer, with recommendations to consume over 300 grams daily, focusing on deep green and red/purple varieties for their antioxidant properties [1][5] - Fruits serve as a source of vitamins, particularly citrus fruits for vitamin C, with a suggested intake of 200 to 350 grams of fresh fruit daily, avoiding fruit juices [3] Group 2 - Whole grains like brown rice and oats are recommended for their dietary fiber content, with a daily intake of 50 to 150 grams, and legumes are noted for their positive effects on hormone-related cancers [5][6] - The article warns against excessive consumption of seven types of foods that increase cancer risk, including high-sugar foods, processed meats, and alcohol [6][8] - It highlights that high sugar intake can lead to metabolic diseases, which are significant risk factors for cancer, due to increased inflammation levels [6][8] Group 3 - Regular screening is emphasized as a key to early cancer detection, with specific recommendations for different types of cancer based on age and risk factors [7][9][10] - For lung cancer, annual low-dose CT scans are advised for individuals over 40 with a significant smoking history, while colorectal cancer screening should start at age 45 [9][10] - Other cancers, such as gastric and liver cancer, have specific screening guidelines based on risk factors like age, alcohol consumption, and pre-existing conditions [10]

Core Viewpoint - The article emphasizes the importance of nutrition in cancer prevention and management, highlighting specific dietary recommendations and foods to avoid to reduce cancer risk [1][3]. Group 1: Dietary Recommendations for Cancer Prevention - Vegetables are identified as the main "anti-cancer" foods, particularly deep green and red/purple varieties, which are rich in antioxidants [2]. - Daily vegetable intake should exceed 300 grams, with a focus on a variety of colors, ideally half being dark vegetables [2]. - Fruits are essential for vitamin supply, with a recommendation of 200-350 grams of fresh fruit daily, avoiding fruit juices [2]. - Whole grains like brown rice, oats, and whole wheat bread are recommended for their dietary fiber content, with a daily intake of 50-150 grams [2]. - Legumes are highlighted as a source of quality plant protein and beneficial for hormone-related cancers [2]. - A balanced diet should include a variety of food groups, including vegetables, fruits, grains, proteins, and healthy fats [2]. Group 2: Foods to Avoid - Seven categories of foods are identified that may increase cancer risk if consumed excessively, including processed meats, fried foods, improperly pickled foods, moldy foods, alcoholic beverages, very hot foods, and high-sugar foods [3]. - High sugar intake can lead to metabolic diseases, which are significant risk factors for cancer, due to the inflammatory processes they trigger [3]. Group 3: Dietary Guidelines for Cancer Patients - Cancer patients are advised not to blindly avoid foods but to focus on a balanced diet that supports recovery [4][5]. - High-inflammatory foods, such as refined sugars and overly processed carbohydrates, should be limited [5]. - A focus on high-quality proteins, healthy fats, and a variety of vegetables is crucial for cancer patients [5][6]. - Three core dietary combinations are recommended: sufficient quality protein at every meal, increased intake of fresh fruits and vegetables, and balanced meal proportions [6]. - Cooking methods should favor steaming, boiling, or stewing to ease digestion, and meals should be fresh and prepared in smaller portions if appetite is low [6]. Group 4: Cancer Screening Recommendations - Regular screening is emphasized as a key strategy for early cancer detection, with specific recommendations for different types of cancer based on age and risk factors [7][8][9][10].

Core Viewpoint - The 27th "World Cancer Day" on February 4, 2026, emphasizes a human-centered approach to cancer prevention, screening, and treatment, highlighting that one-third of cancers are preventable and one-third are curable [1] Group 1: Cancer Prevention - Smoking cessation and avoiding secondhand smoke are crucial, as smoking is the primary cause of lung cancer; quitting smoking can reduce lung cancer risk by 50% after 10-15 years [1] - A balanced diet rich in fresh fruits, vegetables, whole grains, and quality proteins is essential; avoiding moldy foods, high-salt preserved foods, and processed meats can lower cancer risk [1] - Regular physical activity of at least 150 minutes per week and limiting alcohol consumption are recommended to reduce the risk of various cancers [1] Group 2: Early Detection - Regular screening is vital for early cancer detection, with specific recommendations for different types of cancer: - Lung cancer screening for individuals over 50 with a smoking history of 20 pack-years, using low-dose spiral CT annually [2] - Colorectal cancer screening starting at age 45 with fecal occult blood tests and colonoscopy if results are abnormal [3] - Stomach cancer screening for individuals over 40 in high-risk areas or those infected with Helicobacter pylori, using regular gastroscopy [4] - Liver cancer screening for long-term drinkers and patients with hepatitis B or cirrhosis, with semi-annual serum alpha-fetoprotein tests and liver ultrasounds [5] - Breast cancer screening for women starting at age 40 with mammograms every 1-2 years, and high-risk women starting at age 35 annually [6] - Cervical cancer screening for women over 25 with cytology tests, and HPV testing for those over 30 [7] - Prostate cancer screening for men starting at age 50 every 2 years, and high-risk men starting at age 45 annually with PSA tests and digital rectal exams [8] Group 3: Treatment and Support - Upon cancer diagnosis, patients should avoid pseudoscientific treatments and seek care from reputable medical institutions, utilizing precision radiotherapy and targeted therapies to improve survival rates and quality of life [9] - Psychological support is crucial during cancer treatment, with professional counseling, peer support, music therapy, and rehabilitation exercises recommended to enhance mental and physical well-being [9] - The call for collective societal effort emphasizes that everyone should take responsibility for their health, combining healthy habits, proactive screening, scientific treatment, and social support to build a comprehensive defense against cancer [9]

Core Viewpoint - The article discusses the relationship between tumor markers and cancer, emphasizing that elevated tumor marker levels do not necessarily indicate cancer and can be influenced by various factors such as inflammation, infection, and diet [4][5]. Group 1: Understanding Tumor Markers - Tumor markers are substances produced by tumor cells or in response to tumor cells, primarily consisting of proteins, hormones, enzymes, and oncogene products [4]. - They can be found in cells, tissues, blood, or bodily fluids and require specific samples for detection through biochemical and immunological methods [4]. - Elevated tumor marker levels may indicate a potential association with tumors, but they are not definitive for cancer diagnosis [5]. Group 2: Common Tumor Markers and Associated Cancers - Common tumor markers include: - Alpha-fetoprotein (AFP): Indicates primary liver cancer [6] - Carcinoembryonic antigen (CEA): Indicates colorectal, gastric, and pancreatic cancers [6] - Cancer antigen 125 (CA125): Indicates ovarian cancer [6] - Cancer antigen 199 (CA199): Indicates pancreatic, hepatobiliary, and gastric cancers [6] - Prostate-specific antigen (PSA): Indicates prostate cancer [6] Group 3: Dietary Influences on Tumor Markers - Certain foods can temporarily elevate tumor marker levels and may increase cancer risk with long-term consumption [7]. - Processed meats, such as sausages and bacon, can cause transient increases in CEA levels due to chronic inflammation in the digestive tract [8]. - High sugar and refined carbohydrates can lead to increased insulin-like growth factor (IGF) secretion, potentially causing chronic inflammation and fluctuations in CA125 levels [10][11]. - High-purine foods, like organ meats and seafood, can elevate uric acid levels, leading to temporary fluctuations in CA199 [12]. - Alcohol consumption can increase liver burden, potentially causing mild elevations in AFP and affecting CA199 levels, with a higher risk of various cancers associated with frequent drinking [13]. Group 4: Recommendations for Elevated Tumor Markers - Upon discovering elevated tumor markers, it is advised to consult a specialist at a reputable hospital for further evaluation [14]. - Isolated elevations in tumor markers may not be clinically significant and should be assessed in the context of overall health [14]. - A follow-up examination is recommended after one month if initial results show slight elevations [15]. - Continuous monitoring at the same medical institution is suggested to ensure consistency in results [16]. - Specific characteristics of elevated tumor markers warrant further investigation, including significant single elevations, persistent increases over multiple tests, multiple markers being elevated, or the presence of related symptoms [17].

聂卫平曾在中国医学科学院肿瘤医院接受了直肠癌病灶切除手术，肥胖、久坐不动、缺乏锻炼等也是癌 症风险加剧的重要因素。 1月15日，国家体育总局、中国围棋协会等多方确认，中国围棋协会名誉主席聂卫平病逝，享年73岁。 聂卫平九段是我国围棋界的标志性人物之一，也被称为"棋圣"，曾出任围棋国家队总教练，多年来一直 积极参与围棋的推广和普及活动。在上世纪80年代中期的中日围棋擂台赛上，聂卫平连胜多位当时日本 超一流棋手。 1月15日，聂卫平女儿发布讣告称，2013年11月，聂卫平历经癌症手术，术后仍毅然坚守热爱、活跃于 围棋赛场，以顽强意志诠释对围棋的赤诚。他曾多次坦言："只要是对围棋有益处的事情，我都会不遗 余力去做。" 据统计，在我国，包括直肠癌在内的结直肠癌在所有癌症中发病率居第二；而在经济发达地区，如香港 和上海，结直肠癌已经成为消化道肿瘤中发病率第一的恶性肿瘤。 虽然结直肠癌患者以老年人为主，但青年人的结直肠癌发病率也呈逐年增高趋势。由于青年人对结直肠 癌的临床症状缺乏警惕，且相关体检项目较少覆盖青年人，50%至80%的年轻结直肠癌患者确诊时已处 于中晚期。此外，在确诊的青年结直肠癌患者中，60%以上已出现了转 ...

Group 1 - MIRXES-B has established a strategic partnership with N Health to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step in early cancer detection and improving patient outcomes in the region [1] - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1] - The partnership aims to leverage the increasing awareness of preventive healthcare and the rising prevalence of chronic diseases to create an ideal environment for adopting innovative diagnostic technologies like miRNA testing [1] Group 2 - The company launched a new series of home screening test kits in Thailand, including HELICORapid for detecting H. pylori infections and FITRapid for detecting fecal occult blood, both of which are significant cancer risk factors [2] - These home testing kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into a streamlined component, reducing processing steps and minimizing contamination risks [2] - The company aims to expand its sales and marketing efforts into the consumer sector, providing easy-to-use and hygienic home testing options while maintaining scientific rigor and user safety [2]

Core Viewpoint - The controversy surrounding the inability of health check-ups to detect cancer has escalated to legal proceedings, highlighting the limitations of routine screenings in identifying complex diseases like cancer [2][3]. Group 1: Background of the Controversy - A patient, Ms. Zhang, who underwent annual health check-ups at iKang Guobin since 2013, was diagnosed with kidney cancer in 2024 despite normal tumor marker results over the years [2]. - The health check-up results indicated a "renal calcification focus" in 2023, which was deemed normal by the institution's personnel [2]. Group 2: Challenges in Cancer Detection - Cancer is difficult to detect due to its complex nature, with no universal biochemical markers for all types, unlike conditions such as hypertension or diabetes [3]. - Tumor markers like CEA can be influenced by various non-cancerous conditions, leading to potential misinterpretations in screening results [6][7]. Group 3: Economic Aspects of Health Check-ups - The private health check-up industry faces systemic challenges, including high operational costs and low profit margins, with iKang Guobin reporting a net profit margin of -9.3% after rapid expansion [11][12]. - The investment required to establish a health check-up center is substantial, with costs ranging from 10 to 12 million yuan for a facility of 2000-3000 square meters [11]. Group 4: Market Dynamics - Public hospitals serve as a price anchor for private health check-up institutions, limiting their pricing strategies [12]. - The demand for health check-ups is largely driven by corporate clients, with group check-ups accounting for a significant portion of revenue, while individual check-ups remain limited [15][18]. Group 5: Conclusion on the Industry's Viability - The health check-up industry struggles with a flawed business model, acting primarily as intermediaries without core value creation, which complicates their competitive positioning against specialized medical institutions [23].

Financial Data and Key Metrics Changes - Exact Sciences delivered a record 1,300,000 test results, with core revenue growth accelerating to 16% year over year and generating an all-time high of $138,000,000 in adjusted EBITDA [6][8] - Adjusted EBITDA increased by 26%, with an adjusted EBITDA margin expansion of 130 basis points [9] - GAAP net income was negative $1,000,000, including $15,000,000 in one-time costs related to operational efficiency [9] - Free cash flow was $47,000,000, bringing year-to-date free cash flow to $46,000,000, an increase of $95,000,000 compared to the same period last year [9] Business Line Data and Key Metrics Changes - Screening revenue increased by 18% to $628,000,000, driven by rescreens, CareGAP programs, and improved commercial execution [8] - Precision Oncology revenue increased by 9% to $179,000,000 on a core basis, led by Oncotype DX adoption internationally [8] Market Data and Key Metrics Changes - Cologuard brand awareness reached all-time highs, with 2,500,000,000 media impressions driven by increased digital investment [16] - The colon cancer screening landscape is shifting towards a Cologuard-first approach, as indicated by recent advocacy from the AGA work group [16] Company Strategy and Development Direction - The company is raising total revenue guidance to between $3,130,000,000 and $3,170,000, with a focus on expanding its portfolio of advanced cancer tests [11][12] - A multi-year productivity plan targeting $150,000,000 in annual savings by 2026 has been introduced, focusing on operational efficiencies and AI integration [12] - The company aims for a long-term target of 15% compounded revenue growth and more than 20% adjusted EBITDA margins by 2027 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong commercial execution and increased provider engagement [14][15] - The company is optimistic about the potential of Cologuard Plus and the new blood-based colorectal cancer screening tests, despite some setbacks in R&D [18][19] - Management emphasized the importance of maintaining strong relationships with healthcare providers and leveraging their commercial infrastructure to drive growth [22][23] Other Important Information - The company has secured favorable contracts with two of the top 10 payers, Humana and Centene, representing about 40,000,000 members [17] - The company is launching CancerGuard, a blood-based multi-cancer early detection test, addressing a significant unmet clinical need [23] Q&A Session Summary Question: Strategic fit of the Phrenome agreement - Management highlighted that the agreement adds a blood-based option to their portfolio, enhancing their leadership in noninvasive screening [30] Question: Factors contributing to strong growth - Management noted multiple tailwinds, including the launch of Cologuard Plus and improvements in commercial execution [35][38] Question: Blood test performance and FDA submission timeline - Management stated that they are confident in the performance of the Phrenome test and are awaiting FDA submission outcomes [41][80] Question: Resource allocation and strategic prioritization - Management emphasized their commitment to R&D and the potential of the multi-cancer screening market, while addressing concerns about past acquisitions [52][56] Question: Market share for blood-based testing - Management projected that blood-based testing could capture 5% to 10% of the market, depending on future guideline recommendations [91] Question: Confidence in Phrenome's clinical study rigor - Management expressed high confidence in the quality of Phrenome's study design and data, which contributed to their decision to enter the agreement [81]